Dr. Reddys Laboratories has invested USD 620 million in preference shares of its wholly-owned subsidiary, Dr. Reddys Laboratories SA, for the acquisition of Nicotinell and related brands from Haleon Group, with DRL SAs turnover for CY2023 being USD 392 million.